ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Emcure reported strong Q1 FY27 momentum with revenue of INR 92,035 Mn and PAT of INR 9,413 Mn for FY26. Strategy focuses on chronic-led domestic expansion and differentiated international portfolios.
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure's Q1 FY27 results show strong performance driven by international markets and HIV (ARV) business, despite a transitional period in domestic operations following organizational restructuring and the acquisition of Sanofi and Roche portfolios.
Emcure reported Q1 FY27 revenue growth of 22.8% YoY with PAT margins expanding 110 bps. Growth was driven by a 34.2% surge in International Business (58% of total revenue).
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,580 Cr (+22.8% YoY) and net profit of ₹292.5 Cr (+36.2% YoY) for Q1 FY27.
Emcure surpassed $1 billion in revenue in FY26, growing 16.6% YoY with 41% adjusted PAT growth, driven by strong international performance and domestic expansion.
Emcure surpassed $1B revenue in FY26, driven by strong international growth and high-end niche launches despite a temporary restructuring-led slowdown in their Zuventus portfolio.
Emcure crossed $1Bn revenue milestone in FY26, delivering 16.6% growth and margin expansion. Focus remains on scaling international markets and strategic domestic partnerships (Novo Nordisk, Sanofi, Roche).
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,470 Cr (+16.7% YoY) and net profit of ₹243.7 Cr (+23.6% YoY) for Q4 FY26.